SOMAHLUTION ANNOUNCES EACTS ACCEPTANCE OF GROUNDBREAKING ORAL ABSTRACT
Jupiter, FL (July 28, 2016) – Somahlution, a global biotechnology company focused on developing solutions for ischemia reperfusion injury through the development of innovative products that improve clinical outcomes in organ, tissue and surgical conduit transplantation, is pleased to announce that Miguel Haime, MD of VA Boston Healthcare System and Boston Medical Center will present an oral abstract Tuesday, October 4th at 8:47AM at the Rapid Response session of this year’s EACTS meeting in Barcelona, Spain. Dr. Haime will present his abstract entitled “DuraGraft, a one-time intraoperative treatment for the prevention of vein graft failure improves clinical outcomes after coronary artery bypass grafting – Long-term analysis of 2,436 consecutive patients.”
To view the abstract, click here - Somahlution EACTS 2016 Abstract
The study’s objective was to investigate the impact of a novel treatment for intraoperative saphenous vein grafts (DuraGraft Treatment) on short and long-term outcomes in patients undergoing CABG surgery. “This study truly marks a milestone event in the analysis of graft treatment and patient outcomes,” said Dr. Haime. “My hope is these important findings presented at EACTS will bring further awareness to the importance of graft treatment and its correlation with clinical outcomes post CABG.”
The acceptance of this abstract is symbolic of the cardiovascular community’s interest in solving the long-standing problem of vein graft disease leading to vein graft failure following bypass surgery. The intra-operative treatment of bypass conduits with DuraGraft leading to significantly improved outcomes is a major step forward in addressing this problem.
“The presentation at EACTS and the subsequent imminent publication of the VA’s extraordinarily large body of evidence is an important milestone in cardiovascular disease management “said Satish Chandran, CEO of Somahlution. “This study’s results should help to further establish CABG as the treatment of choice for many with multi-vessel coronary artery disease.”
Somahlution is a global leader in the development and commercialization of innovative, high value-added solutions to advance clinical performance, define standard of care and improve patient outcomes. Using patented and proprietary technologies, Somahlution is dedicated to providing medical products focused on Ischemia Reperfusion Injury (IRI) to improve healthcare delivery to patients around the world. The company’s flagship product, DuraGraft, is a one-time intraoperative treatment for the prevention of vein graft failure and improves clinical outcomes after coronary artery bypass grafting surgery. For more information about the company, please visit www.somahlution.com.
- # # # -
Back to the latest news